A promising new test is detecting prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein, according to Cleveland Clinic ...
A new blood-based diagnostic test (IsoPSA) for prostate cancer that evaluates structural changes in prostate-specific antigen could reduce unnecessary biopsies and identify the right patients that ...
IsoPSA Test Evaluates Prostate Cancer-Specific Structural Variants of the PSA Protein to Aid in the Diagnosis of High-Grade Prostate Cancer CLEVELAND, December 01, 2025--(BUSINESS WIRE)--Cleveland ...
CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its ...
CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today two ...
Using the prostate-specific antigen test to screen for prostate cancer is controversial: First, doctors used to perform it on nearly every man over 50. Then in 2012, the U.S. Preventive Task Force ...
A PSA or test prostate-specific antigen test after 50 years of age is usually advised to men to check on the status of their prostate gland. An elevated level of PSA in the blood is seen as an ...
A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA ...
Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, has opened a new, state-of-the-art facility. The ...
A new blood test called IsoPSA has been developed by researchers, that helps in detecting prostate cancer and reduces the rate of biopsies by almost 50 percent. IsoPSA, a new blood test detects ...
CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results